Price Chart
Key Statistics
Market Cap(EOD)328.39M
Enterprise Value225.77M
P/E Ratio (TTM)-18.23
P/B Ratio (TTM)4.95
P/S Ratio (TTM)0.00
Earnings Yield (TTM)-5.49%
ROE (TTM)-37.19%
ROIC (TTM)-30.59%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.01
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.